Hematology

The combination therapy of ibrutinib and venetoclax was superior to chlorambucil and obinutuzumab in terms of undetectable minimal residual disease responses in elderly or unfit patients with previously untreated chronic lymphocytic leukemia.

Daratumumab continued to demonstrate deep and durable responses, including improvements to stringent complete response (sCR) rates and minimal residual disease (MRD)-negativity.

Axicabtagene ciloleucel (Yescarta) was the first CAR T-cell immunotherapy to be approved for relapsed or refractory large B-cell lymphoma.

Factor V Leiden can increase the chance of developing abnormal blood clots, most commonly in the legs or lungs.

Rylaze is a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma.

FDA to evaluate luspatercept-aamt (Reblozyl) for the treatment of anemia in adults with non–transfusion dependent β-thalassemia.

FDA approves rituximab (Rituxan) plus chemotherapy for pediatric patients with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia.

Ibrutinib in combination with venetoclax shows promise in patients with previously untreated chronic lymphocytic leukemia.

The combination of daratumumab with hyaluronidase (Darzalex Faspro), hyaluronidase-fihj, carfilzomib (Kyprolis), and dexamethasone is indicated for the treatment of adult patients with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy.

Further, at daily doses of at least 100 mg, the rates of VTE with milvexian were significantly lower than with enoxaparin, according to the study authors.

Besermi is an interferon alfa-2b indicated for the treatment of adults with polycythemia vera.

Within 1 or 2 days of injury, therapeutic B cells release a complex mix of specific pro- and anti-inflammatory molecules, which can affect molecular processing and facilitate healing.

Rituximab-pvvr is indicated for the treatment of adult patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, and granulomatosis.

Study finds COVID-19 booster shot was extremely beneficial for all patients with cancer, especially those with a blood cancer.

Hodgkin lymphoma is most common in people between 20 and 40 years of age and those over 55 years of age.

The panel also recommends considering risk factors for poor response, including uncontrolled disease, immunoparesis, the number of previous lines of therapy, and patient age.

Kymriah is a CD19-directed genetically modified autologous T-cell immunotherapy.

No new safety concerns were encountered, which the investigators said support the frontline use of daratumumab plus lenalidomide and dexamethasone for patients with multiple myeloma who are ineligible for transplantation.

Jennifer Andrews, MD, pediatric hematologist-oncologist at Vanderbilt University Medical Center and medical director of Vanderbilt University Medical Center’s blood bank, discusses what health systems can do to address the national blood shortage and increase blood donations.

Ciltacabtagene autoleucel (cilta-cel) CAR T-cell therapy is currently being evaluated for the treatment of patients with relapsed and/or refractory multiple myeloma.

Deep vein thrombosis can occur with certain medical conditions that affect how the blood clots.

Pembrolizumab (Keytruda) can be used for multiple cancer types, including melanoma, non-small cell lung cancer, and head and neck squamous cell cancer.

Asciminib (Scemblix) approved for patients with Philadelphia chromosome–positive chronic myeloid leukemia (CML) in chronic phase who were previously administered 2 or more tyrosine kinase inhibitors.

Patients undergoing chemotherapy had lower COVID-19 antibody levels than patients undergoing targeted therapy following vaccination.

Jennifer Andrews, MD, pediatric hematologist-oncologist at Vanderbilt University Medical Center and medical director of Vanderbilt University Medical Center’s blood bank, discusses how a national blood shortage could affect patient care and outcomes.

Jennifer Andrews, MD, pediatric hematologist-oncologist at Vanderbilt University Medical Center and medical director of Vanderbilt University Medical Center’s blood bank, discusses what the national blood shortage may mean for health systems.

Avacopan (Tavneos, ChemoCentryx) met its primary endpoints of disease remission at 26 weeks and sustained remission at 52 weeks during a phase 3 trial in patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis.

Isatuximab-irfc (Sarclisa; sanofi-aventis) provides patients with another option for treatment and significantly reduces the risk of disease progression or death.

A single infusion of the CAR T-cell therapy Tecartus produced a high and durable response rate in heavily pretreated patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Among 38 patients with B-cell derived malignancies who were seronegative after 2 COVID-19 vaccine doses, 55% had detectable antibodies after the third dose whereas 45% remained seronegative.